Global X Telemedicine & Digital Health ETF

Hims & Hers Health Increases Convertible Note Offering to $350 Million

Hims & Hers debuts first AI agent, Labs AI

Tempus AI to participate in the 2026 ASCO® Annual Meeting

Tempus AI will host an Investor Day on May 29, 2026

Tempus AI will hold its Annual General Meeting on May 21, 2026

Law Firm Investigates Hims & Hers Health for Potential Corporate Wrongdoing

Hims & Hers Health Reports Net Loss in Q1 2026 Results, Leading to Stock Volatility

Hims & Hers Health expects to close its acquisition of Eucalyptus in mid-2026.

Barclays Downgrades Doximity to Hold, Peers Cut Price Targets

RBC Maintains Buy Rating on Doximity with $28 Target, Goldman Sachs Issues Hold

Investment group Susquehanna discloses a 6.5% passive stake in Hims & Hers

Hims & Hers reports Q1 earnings with an unexpected loss of $0.40 per share, but raises full-year revenue forecast

Tempus AI to Hold Annual General Meeting on May 20, 2026

Tempus AI to Host Inaugural Investor Day on May 29, 2026

Tempus AI Expands Strategic Collaboration with Bristol Myers Squibb in Oncology and Neuroscience

Capital World Investors discloses its stake in Hims & Hers

RBC Capital Analyst Maintains Hold Rating on Royal Philips with a Price Target of €25

Macquarie and Citibank Reiterate Buy Rating on ResMed CHESS Depositary Interests

Doximity released FY2026 Q4 earnings on May 13 After-Market EST, actual revenue USD 145.37 M (forecast USD 143.91 M), actual EPS USD 0.1 (forecast USD 0.1723)

Doximity released FY2026 Annual Earnings on May 13 After-Market (EST), actual revenue USD 644.86 M (forecast USD 643.55 M), actual EPS USD 0.98 (forecast USD 1.0695)

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

TDOC

HEAL

EDOC

FDHT

UBS analyst Kevin Caliendo has maintained a Hold rating on Teladoc (TDOC) with a price target of $6.00. Caliendo, a 4-star analyst, has an average return of 3.5% and a 53.71% success rate. Previously, Citi's Daniel Grosslight also issued a Hold rating, while Canaccord Genuity maintained a Buy rating on April 30.

Tip Ranks

Teladoc

Global X HealthTech ETF

Fidelity Digital Health ETF

UBS Group AG

Dentsply Sirona

Cencora

Henry Schein

Citigroup

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Teladoc (TDOC) Gets a Hold from UBS

Shares of Teladoc Health (TDOC) rose over 4% on Friday, marking a seven-session winning streak and a total gain of approximately 22% since April 30. Despite a 38% increase over the past month, the stock is up only 2.7% year-to-date, lagging behind the S&P 500's 7% gain. Analysts highlight Teladoc's shift to a data-driven B2B healthcare model and improving financial metrics as positive indicators for future growth. Among 26 analysts, six rate the stock as a "strong buy," while one rates it as "buy" and 19 as "hold."

Teladoc Health extends rally to seventh straight session, gaining 22%

TD Cowen analyst Charles Rhyee has reaffirmed a Hold rating on Teladoc (TDOC) stock, citing tightened 2026 guidance for revenue and adjusted EBITDA margins. He projects adjusted EBITDA of $279 million for 2026 and $289 million for 2027, with Integrated Care contributing $251 million and BetterHelp $28 million. Rhyee maintains a $6 price target, indicating limited upside. Evercore ISI also holds a $6 price target on the stock, reflecting a neutral stance.

Evercore

Teladoc Hold Rating Reaffirmed as 2026 Outlook Tightens and $6 DCF-Based Price Target Remains Unchanged

Teladoc Health (NYSE:TDOC) reported Q1 2026 results with revenue of $614M and Adjusted EBITDA of $58M, exceeding guidance. CEO Chuck Divita highlighted a shift from subscription to visit-based care, which is seen as a near-term challenge but an opportunity for growth. Integrated Care revenue grew 1.5% to $395M, while BetterHelp revenue declined 9% to $218M. The company is investing in AI and expects to release new products later in 2026. Teladoc maintains its full-year outlook despite potential enrollment changes in health plans.

Market Beat

Peloton Interactive

Teladoc Health Q1 Earnings Call Highlights

Teladoc Inc. (TDOC) has maintained its risk disclosures in its latest Form 10-Q, indicating no material updates from its previous Form 10-K. This raises concerns about potential regulatory, competitive, operational, and macroeconomic pressures that could impact performance. The unchanged risk profile may suggest stability or a failure to recognize new threats, prompting increased scrutiny from investors. The average stock price target for TDOC is $7.16, indicating an 18.15% upside potential.

Unchanged Risk Disclosures at Teladoc Raise Questions About Emerging Threats and Investor Exposure

Earnings Snapshot: Teladoc Health issues weak Q2 revenue outlook after mixed Q1 results

businessinsider

Earnings Snapshot: Teladoc Health issues weak Q2 revenue outlook after mixed Q1 results

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

nasdaq

Nasdaq

Teladoc (TDOC) Q1 2026 Earnings Transcript

Teladoc Health (NYSE:TDOC) shares fell 5.6% to $5.62 after reporting mixed Q1 earnings. Revenue was $613.8 million, down 2% year-over-year, but above estimates. The company reported a net loss of 36 cents per share, missing expectations. Guidance for Q2 revenue is set between $597 million and $626 million, with a projected loss of 30 to 20 cents per share. For the full year, revenue guidance is narrowed to $2.481 billion to $2.576 billion, with an expected loss of $1.05 to $0.75 per share. CEO Chuck Divita emphasized a focus on strategic execution and long-term value.

benzinga_article

Teladoc Shares Fall After Q1 Earnings: What Investors Need To know

Teladoc Health is set to report earnings after market close on Wednesday. Last quarter, it reported revenues of $642.3 million, flat year-on-year, but missed revenue and EBITDA guidance for the next quarter. Analysts expect a 3% revenue decline this quarter. Despite missing estimates multiple times in the past two years, analysts have maintained their estimates. Teladoc's stock has risen 15.2% recently, with an average analyst price target of $7.09 against a current price of $5.92.

Stock Story

Coursera

Netflix

NVIDIA

NVIDIA Corporation

Teladoc (TDOC) Reports Earnings Tomorrow: What To Expect

PYPL

PYPG

The article discusses the potential of Teladoc Health and PayPal as investment opportunities. Both companies have seen significant declines, with Teladoc facing competition and profitability issues, while PayPal's growth has stalled post-pandemic. Despite challenges, PayPal is viewed positively due to its brand strength and growth prospects in digital advertising. Investors are cautioned to consider alternatives, as PayPal was not included in a list of top recommended stocks. Overall, Teladoc is seen as a risky investment, while PayPal may offer long-term potential if it can capitalize on its strengths.

- Teladoc Health is facing significant competition and profitability challenges, leading to its stock performance lagging in recent years.  
- Conversely, PayPal has established a strong brand and network effects, with growth opportunities in digital advertising despite a slowdown in user growth.  
- While Teladoc is seen as a risky investment, PayPal is regarded as a potential buy due to its long-term growth prospects.

Paypal

Leverage Shares 2X Long PYPL Daily ETF

Intel

Are These Beaten-Down Stocks Generational Opportunities or Value Traps?

Global X Telemedicine & Digital Health ETF(EDOC.US)

Teladoc (TDOC) Gets a Hold from UBS

Teladoc Health extends rally to seventh straight session, gaining 22%

Teladoc Hold Rating Reaffirmed as 2026 Outlook Tightens and $6 DCF-Based Price Target Remains Unchanged

Teladoc Health Q1 Earnings Call Highlights

Unchanged Risk Disclosures at Teladoc Raise Questions About Emerging Threats and Investor Exposure